- Lawsuit alleges YouTube’s unboxing videos are ‘abusive’ ads aimed at kids Sunday 3:48 PM
- Dr. Dre shades Lori Loughlin with Instagram flex about his daughter getting into USC Sunday 3:13 PM
- University of Georgia frat’s racist Snapchat video draws campus outrage Sunday 1:21 PM
- Facing criticism for eating fish, vegan YouTube star Rawvana speaks out Sunday 10:47 AM
- Arnold Schwarzenegger chases mini-pony in new TikTok video Sunday 9:19 AM
- Review: ‘Sekiro: Shadows Die Twice’ is a cut above the rest Sunday 8:00 AM
- Where do 2020 Democratic candidates stand on healthcare? Sunday 7:30 AM
- How to (legally) stream live TV on Kodi Sunday 7:00 AM
- ‘Delhi Crime’ tackles inequality and women’s rights Sunday 7:00 AM
- How to watch the 2019 STP 500 at Martinsville Speedway for free Sunday 6:00 AM
- These high school theater kids put on a totally awesome ‘Alien’ play Saturday 3:59 PM
- Behold these photos of Elon Musk, but with Elizabeth Holmes’ eyes Saturday 3:11 PM
- Barbra Streisand gets ‘canceled’ over remarks about Michael Jackson’s alleged victims Saturday 2:09 PM
- Report: Florida man raped Texas teen after posing as Instagram celeb Saturday 12:14 PM
- Lori Loughlin’s daughters, Olivia and Isabella, could be banned from USC forever Saturday 11:46 AM
The FDA just approved a genetic testing kit and set a major precedent
The kits will still be marketed under FDA scrutiny.
The FDA will allow the company to sell a kit that tests people for Bloom Syndrome, a rare genetic disorder resulting in shorter height and a higher likelihood of developing cancer. The decision comes two years after the FDA ordered 23andMe to stop selling its tests because they had failed to gain regulatory approval.
“This is also the first-time the FDA has granted authorization to market a direct-to-consumer genetic test, and it gives 23andMe a regulatory framework for future submissions,” 23andMe CEO Anne Wojcicki wrote in a blog post, explaining that the decision paved the way for the company to begin selling other genetic testing kits.
The FDA ruling is notable because it establishes exactly how at-home genetic testing kits are defined by government regulators. Based on this ruling, the Bloom Syndrome kit is classified as a class II medical product, making it subject to special advertising restrictions but allowing it to be sold directly to consumers.
In another win for 23andMe, updated versions of Class II products like this kit do not require FDA pre-review before going to market.
Alberto Gutierrez, the FDA’s director of vitro diagnostics and radiological health, said in a statement that his agency “believes that in many circumstances it is not necessary for consumers to go through a licensed practitioner to have direct access to their personal genetic information.”
Not only is 23andMe allowed to resume selling its tests, but the FDA ruling could also help the company prevail in several ongoing class action lawsuits. Several consumers have sued 23andMe for false advertising, claiming that their marketing materials failed to disclose their products’ lack of FDA approval.
Despite this nod of approval from federal regulators, 23andMe still faces criticism from privacy advocates who worry about the fact that the company stores the genetic data of its users.
Tim Sampson is a reporter who focused on the technology, business, and politics beats. He's also an established comedy writer, with work on Comedy Central and in The Onion and ClickHole.